Price Alert

Strongbridge Biopharma (SBBP)

NASDAQ: SBBP · Real-Time Price · USD

2.00

0.03 (1.52%)

At close: Apr 24, 2025, 3:47 PM

Strongbridge Biopharma Statistics

Share Statistics

Strongbridge Biopharma has 0 shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 352.58K, so 0% of the outstanding shares have been sold short.

Short Interest	352.58K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.8

Valuation Ratios

The PE ratio is -3.02 and the forward PE ratio is null. Strongbridge Biopharma's PEG ratio is 0.3.

PE Ratio	-3.02
Forward PE	n/a
PS Ratio	4.44
Forward PS	n/a
PB Ratio	2.08
P/FCF Ratio	-3.57
PEG Ratio	0.3

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Strongbridge Biopharma.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.37, with a Debt / Equity ratio of 0.28.

Current Ratio	4.37
Quick Ratio	4.32
Debt / Equity	0.28
Debt / EBITDA	-0.47
Debt / FCF	-0.48
Interest Coverage	-32.31

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$426.82K
Profits Per Employee	$-626.04K
Employee Count	72
Asset Turnover	0.25
Inventory Turnover	2.01

Taxes

Income Tax	-15K
Effective Tax Rate	0.03%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 1.6, so Strongbridge Biopharma's price volatility has been higher than the market average.

Beta	1.6
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	316,352

Income Statement

In the last 12 months, Strongbridge Biopharma had revenue of 30.73M and earned -45.08M in profits. Earnings per share was -0.8.

Revenue	30.73M
Gross Profit	28.52M
Operating Income	-43.16M
Net Income	-45.08M
EBITDA	-38.65M
EBIT	-43.75M
Earnings Per Share (EPS)	-0.8

Full Income Statement

Balance Sheet

The company has 87.52M in cash and 18.19M in debt, giving a net cash position of 69.33M.

Cash & Cash Equivalents	87.52M
Total Debt	18.19M
Net Cash	69.33M
Retained Earnings	-305.56M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -38.13M and capital expenditures -10K, giving a free cash flow of -38.14M.

Operating Cash Flow	-38.13M
Capital Expenditures	-10K
Free Cash Flow	-38.14M
FCF Per Share	-0.68

Full Cash Flow Statement

Margins

Gross margin is 92.8%, with operating and profit margins of -140.46% and -146.68%.

Gross Margin	92.8%
Operating Margin	-140.46%
Pretax Margin	-146.72%
Profit Margin	-146.68%
EBITDA Margin	-125.76%
EBIT Margin	-140.46%
FCF Margin	-124.12%

Dividends & Yields

SBBP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for SBBP.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a